BJH - volume 16, issue 1, february 2025
E. Dewulf MSc
SUMMARY
During ASH 2024, the role of autologous stem cell transplantation (ASCT) for patients with mantle cell lymphoma (MCL) was questioned in the TRIANGLE and ECOG-ACRIN EA4151 trials. In addition, the ENRICH trial evaluated the efficacy and safety of a chemotherapy-free regimen for older patients with untreated MCL. Regarding diffuse large-B-cell lymphoma (DLBCL), extended follow-up data of the POLARIX trial were presented, comparing R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) to pola-R-CHP (polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisone) as first-line treatment. Also, the addition of the bispecific antibody glofitamab to R-CHOP or pola-R-CHP was evaluated in the COALITION trial, including younger patients with high-risk DLBCL. Finally, interim results of the DALY II trial were presented, assessing the feasibility, safety and efficacy of chimeric antigen receptor T (CAR T)-cell therapy with zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL.
(BELG J HEMATOL 2025;16(1):41–6)
Read more
Top
